Group 1 - The legal opinion letter is issued by Zhejiang Tiance Law Firm regarding the differentiated equity distribution plan of Zhejiang Jiuzhou Pharmaceutical Co., Ltd for the first half of 2025 [1][2] - The company plans to distribute a cash dividend of 2.00 yuan (including tax) for every 10 shares to all shareholders [4][5] - The total share capital of the company is 889,446,028 shares, with 7,736,000 shares held in the repurchase special securities account, which will not participate in the profit distribution [4][5] Group 2 - The actual number of shares participating in the dividend distribution is calculated by deducting the shares in the repurchase account from the total share capital, resulting in a total of 881,710,028 shares eligible for the cash dividend [5][7] - The total cash dividend to be distributed amounts to 176,342,005.60 yuan (including tax) [5] - The ex-dividend reference price is calculated based on the closing price before the dividend distribution, which is 18.58 yuan per share, leading to an adjusted reference price of 18.38 yuan per share after accounting for the cash dividend [6][7] Group 3 - The legal opinion concludes that the differentiated equity distribution complies with relevant laws and regulations, including the Company Law and Securities Law, and does not harm the interests of the company or its shareholders [5][7]

Core Points - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. announced a cash dividend of 0.20 CNY per share for A shares [1][5] - The record date for the dividend is September 5, 2025, with the ex-dividend date and payment date both on September 8, 2025 [1][5] - The total cash dividend distribution amounts to approximately 176.34 million CNY, representing 52.93% of the company's net profit attributable to shareholders for the first half of 2025 [3][2] Dividend Distribution Plan - The company's board of directors was authorized to formulate the specific distribution plan at the annual general meeting held on May 8, 2025, and the plan was approved on August 5, 2025 [1][2] - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the record date [1][2] Share Repurchase and Taxation - Shares repurchased by the company will not participate in profit distribution [5][6] - The actual cash dividend received by individual shareholders will be 0.20 CNY per share, with tax implications based on the holding period of the shares [6][7] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net dividend of 0.18 CNY per share [7]

浙江天册律师事务所 关于 浙江九洲药业股份有限公司 2025 年半年度差异化权益分派事项的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 0 法律意见书 浙江天册律师事务所 关于 浙江九洲药业股份有限公司 2025 年半年度差异化权益分派事项的 法律意见书 编号：TCYJS2025H1364 号 致：浙江九洲药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江九洲药业股份有限公司（以 下简称"九洲药业"或"公司"）的委托，就公司 2025 年半年度利润分配方案所 涉及的差异化权益分派（以下简称"本次差异化权益分派"）相关事宜，根据《中 华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司股份回购规则》（以下简称"《回购规 三、本所律师对与出具本法律意见书有关的所有文件、资料等进行了合理核查、 判断，并据此发表法律意见。对本法律意见书至关重要而又无法得到独立的证据支 持的事实，或者基于本所专业无法作出核查及判断的重要事实，本所依赖政府有 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-055 浙江九洲药业股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.20元。 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/5 | － | 2025/9/8 | 2025/9/8 | 差异化分红送转：是 一、 通过分配方案的股东会届次和日期 浙江九洲药业股份有限公司（以下简称"公司"）2025 年 5 月 8 日的2024年 年度股东大会授权董事会在符合利润分配条件的情况下制定具体的分配方案，本 次利润分配方案经 2025 年 8 月 5 日召开的第八届董事会十六次会议审议通过。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分 ...

Group 1 - The core viewpoint of the news is that Jiuzhou Pharmaceutical experienced a stock price increase of 5.14%, reaching 19.02 CNY per share, with a trading volume of 594 million CNY and a turnover rate of 3.61%, resulting in a total market capitalization of 16.917 billion CNY [1] - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates. The revenue composition is as follows: 79.81% from new drug custom development and manufacturing services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Group 2 - Among the top circulating shareholders of Jiuzhou Pharmaceutical, a fund under China Europe Fund holds a significant position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 4.3884 million shares in the second quarter, now holding 13.4263 million shares, which accounts for 1.51% of the circulating shares. The estimated floating profit today is approximately 12.4865 million CNY [2] - The China Europe Medical Health Mixed A Fund (003095) was established on September 29, 2016, with a current scale of 15.638 billion CNY. Year-to-date returns are 28.82%, ranking 2520 out of 8254 in its category; the one-year return is 43.11%, ranking 3274 out of 8037; and since inception, the return is 122.33% [2] Group 3 - The fund managers of the China Europe Medical Health Mixed A Fund (003095) are Ge Lan and Zhao Lei. As of the report, Ge Lan has a cumulative tenure of 10 years and 219 days, with a total fund asset size of 39.908 billion CNY, achieving a best fund return of 125.88% and a worst return of -35.13% during her tenure. Zhao Lei has a tenure of 60 days, managing a fund asset size of 30.801 billion CNY, with a best return of 13.75% and a worst return of 13.59% during his tenure [3]

Core Viewpoint - Jiuzhou Pharmaceutical announced a capital increase of 200 million yuan for the construction of an innovative drug CDMO production base in Taizhou, with the project being implemented by Jiuzhou Pharmaceutical (Taizhou) Co., Ltd. [1] Group 1 - The company will hold the 16th meeting of the 8th Board of Directors and the 10th meeting of the 8th Supervisory Board on August 5, 2025 [1] - The capital increase is aimed at supporting the first phase of the construction project [1] - Jiuzhou Pharmaceutical (Taizhou) has completed the business registration change and obtained a new business license from the Market Supervision Administration of Linhai City [1]

证券代码：603456 证券简称：九洲药业 公告编号：2025-054 7、成立日期：2021 年 2 月 14 日 浙江九洲药业股份有限公司 关于全资子公司完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江九洲药业股份有限公司（以下简称"公司"）于 2025 年 8 月 5 日召开第 八届董事会第十六次会议和第八届监事会第十次会议，审议通过了《关于使用部 分募集资金向募投项目实施主体增资实施募投项目的议案》，同意公司以募集资 金 20,000 万元对"九洲药业（台州）有限公司创新药 CDMO 生产基地建设项目 （一期工程）"实施主体九洲药业（台州）有限公司（以下简称"九洲药业（台 州）"）进行增资。具体内容详见公司于 2025 年 8 月 6 日在《上海证券报》和上 海证券交易所网站披露的相关公告（公告编号：2025-050）。 近日，九洲药业（台州）已完成工商变更登记手续，并取得临海市市场监督 管理局换发的《营业执照》，现将有关情况公告如下： 1、公司名称：九洲药业（台州）有限公司 2、统一社会信 ...

Group 1 - As of August 21, 2025, Jiuzhou Pharmaceutical's stock price is 18.43 yuan, down 0.16 yuan or 0.86% from the previous trading day [1] - The trading volume on that day was 254,225 hands, with a transaction amount of 468 million yuan [1] - Jiuzhou Pharmaceutical focuses on the chemical pharmaceutical sector, primarily engaged in the research, production, and sales of active pharmaceutical ingredients and intermediates [1] Group 2 - The company's product range includes treatments for infections, cardiovascular diseases, and central nervous system disorders [1] - In the second quarter of 2025, the China-Europe Medical Health Fund reduced its holdings in Jiuzhou Pharmaceutical by 4.3884 million shares, although it remains one of the top ten circulating shareholders [1] - On August 21, 2025, the net outflow of main funds for Jiuzhou Pharmaceutical was 83.2752 million yuan, with a cumulative net outflow of 200 million yuan over the past five trading days [1]

Core Insights - The article highlights the significant stock adjustments made by the China Europe Medical Health Fund, managed by Ge Lan, during the second quarter of 2025, particularly its increased holdings in several pharmaceutical companies [1][3][4]. Group 1: Fund Adjustments - The China Europe Medical Health Fund entered the top ten circulating shareholders of Lizhu Group and Betta Pharmaceuticals, holding 5.939 million shares and 4.3513 million shares, respectively [3]. - The fund significantly increased its stake in XinNuoWei by approximately 14 million shares, representing a 222% increase, bringing its total holdings to 20.184 million shares [3][4][6]. - Other notable increases included holdings in XinLiTai (up 86% to 26.163 million shares), NuoCheng JianHua (up 43.9% to 13.048 million shares), and HuaDong Pharmaceutical (up 17.39% to 24.4395 million shares) [4][6]. Group 2: Fund Management Strategy - In July, the China Europe Medical Health Fund announced the appointment of Zhao Lei as a co-manager, indicating a shift towards a team-based management approach [8]. - The fund is part of a broader trend within China Europe Fund to enhance its research and investment management capabilities through a "professional, industrialized, and intelligent" investment research system [8][9]. - This transformation aims to create a sustainable organization capable of generating alpha over the long term, thereby improving product offerings and services for investors [9].

Group 1: Market Overview - The A-share market is currently active, with brokerage analysts conducting extensive research on listed companies as half-year reports are being disclosed [1][2] - A total of 162 companies have been researched by brokerages since August, covering popular sectors such as electronics, pharmaceuticals, machinery, and power equipment [1][2] Group 2: Sector Focus - The electronics, machinery, and pharmaceutical sectors are the most researched, with 22, 20, and 21 companies respectively [2] - The pet sector, particularly Zhongchong Co., Ltd. (002891), has attracted the most attention, with 61 brokerages participating in its recent performance briefing [2][3] Group 3: Company Highlights - Zhongchong Co., Ltd. has established over 22 modern production bases globally and is expanding its projects in various countries, including the US and Canada [3] - Ninebot Inc. has garnered interest from 47 brokerages, focusing on its electric two-wheeler profit margins and the development of its intelligent ecosystem [3] - Jerry Holdings (002353) has been researched by 41 brokerages, with a focus on its business structure and overseas market development [3] Group 4: Pharmaceutical Sector Insights - The pharmaceutical sector has seen significant interest, with over 65 research reports published in August, including 10 deep-dive reports [4] - Companies like Jiuzhou Pharmaceutical (603456) and Sanxin Medical (300453) have been actively researched, with Jiuzhou reporting a net profit of 526 million yuan, a 10.7% increase year-on-year [4][5] - Bo Rui Pharmaceutical has seen its stock price rise over 277% this year, with plans to expand its product offerings globally [5] Group 5: Rating Adjustments - Brokerages have upgraded the ratings of seven companies since August, including Aisheng Co., Ltd. (600732) and Huaneng International (600011) [6] - Huaneng International reported a net profit of 9.262 billion yuan, a 24.26% increase, prompting an upgrade to "buy" rating [6] - One stock, Fuling Pickles (002507), was downgraded from "buy" to "hold" due to slower sales recovery and increased cost pressures [6]